Eupraxia Pharmaceuticals Inc. (EPRX) shareholders
EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.15+0.34 (+4.35%)
Close on Nov 13, 2026Market cap $491.40MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
41.1%
25M of 60M shares
Institutional holders
68
18 new, 5 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Joseph S. Freedman | 5,843,215 | 9.00% | 13D (active) amendment | Mar 13, 2026 |
| Beutel, Goodman & Co Ltd. | 4,058,899 | 8.00% | 13G (passive) | Sep 30, 2025 |
| Morgan C. Frank Joint filing with James E. Besser (7.60%), Manchester Management Company, LLC (7.40%) and 2 more | 4,015,248 | 7.70% | 13G (passive) amendment | Mar 31, 2026 |
| Robert Disbrow | 3,568,150 | 7.00% | 13G (passive) amendment | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EPRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Beutel, Goodman & Co Ltd. | 3,627,864 | 6.02% | $23.81M | −38,601 | 0.18% |
| Affinity Asset Advisors, LLC | 1,650,000 | 2.74% | $10.91M | +60,995 | 0.49% |
| Balyasny Asset Management L.P. | 1,350,015 | 2.24% | $8.92M | +15 | 0.01% |
| Vivo Capital, LLC | 1,350,000 | 2.24% | $8.92M | – | 0.81% |
| Scotia Capital Inc. | 1,343,726 | 2.23% | $8.78M | +1,548 | 0.03% |
| PFM Health Sciences, LP | 1,210,661 | 2.01% | $8.00M | +669,790 | 0.69% |
| Great Point Partners LLC | 1,200,000 | 1.99% | $7.93M | – | 1.50% |
| Jupiter Topco LLC | 1,046,000 | 1.73% | $6.85M | New | 0.00% |
| Rubric Capital Management LP | 867,424 | 1.44% | $5.73M | +176,254 | 0.05% |
| Ikarian Capital, LLC | 809,741 | 1.34% | $5.35M | −405,000 | 0.58% |
| Woodline Partners LP | 746,864 | 1.24% | $4.94M | +306,313 | 0.02% |
| Point72 Asset Management, L.P. | 730,284 | 1.21% | $4.83M | −237,291 | 0.01% |
| Ameriprise Financial Inc | 711,024 | 1.18% | $4.70M | +61,950 | 0.00% |
| Redmile Group, LLC | 611,400 | 1.01% | $4.04M | −88,600 | 0.27% |
| Seven Fleet Capital Management LP | 610,785 | 1.01% | $4.04M | +177,270 | 0.67% |
| UBS Group AG | 519,211 | 0.86% | $3.43M | −243,424 | 0.00% |
| Citadel Advisors LLC | 502,011 | 0.83% | $3.32M | +271,835 | 0.00% |
| Millennium Management LLC | 441,586 | 0.73% | $2.92M | New | 0.00% |
| Alyeska Investment Group, L.P. | 375,000 | 0.62% | $2.48M | – | 0.01% |
| Picton Mahoney Asset Management | 360,878 | 0.60% | $2.39M | New | 0.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 68 | 25M | 41.1% | 18 / 22 | 18 / 5 | 5M | 3M |
| Q1 2026 | 55 | 22M | 36.9% | 22 / 19 | 6 / 3 | 9M | 0M |
| Q4 2025 | 36 | 14M | 23.1% | 15 / 8 | 4 / 6 | 3M | 2M |
| Q3 2025 | 27 | 13M | 21.3% | 15 / 7 | 2 / 2 | 11M | 0M |
| Q2 2025 | 14 | 2M | 4.0% | 3 / 6 | 5 / 0 | 1M | 0M |
| Q1 2025 | 11 | 2M | 3.6% | 4 / 4 | 2 / 2 | 0M | 0M |
| Q4 2024 | 9 | 2M | 3.0% | 2 / 2 | 4 / 1 | 0M | 0M |
| Q3 2024 | 8 | 2M | 3.0% | 3 / 3 | 0 / 3 | 0M | 0M |
| Q2 2024 | 8 | 2M | 2.9% | 8 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of EPRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 36,211 | 0.06% | $256.74K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 300 | 0.00% | $1.98K | 0.00% | Jun 30, 2026 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
11.47%
6M shares short
Days to cover
10.4
At 1M shares a day
Change since last report
-4.5%
From 7M shares
Short volume, 20 days
39.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Eupraxia Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 48,000 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?